Announced
Financials
Sources
Tags
Pending
Pharmaceuticals
Friendly
drug manufacturing
Private Equity
Public
China
Acquisition
Minority
Single Bidder
Cross Border
Synopsis
The Carlyle Group agreed to acquire a 5% stake in Shenzhen Salubris Pharmaceuticals, a Chinese pharmaceutical company, for $260m. Carlyle stepped up health-care investments in China, buying stakes in third party independent clinical laboratory Adicon and global peptide API’s manufacturer Ambio in 2018. Globally, Carlyle has invested more than $13.4bn of equity in more than 80 deals in the global health care sector as of June 2020.
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.